In a significant development for diabetes and cardiovascular care, Eli Lilly has announced that its drug Mounjaro (tirzepatide) has demonstrated clear heart-health benefits in patients with type 2 diabetes and existing cardiovascular disease.
📢 The findings — from a large-scale head-to-head trial — were released on July 31, 2025, and may pave the way for an FDA label update.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
